Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nivolumab/vorhyaluronidase alfa - Bristol-Myers Squibb/Ono Pharmaceuticals

Next Previous
Drug Profile

Nivolumab/vorhyaluronidase alfa - Bristol-Myers Squibb/Ono Pharmaceuticals

Alternative Names: Nivolumab subcutaneous - Bristol-Myers Squibb/Ono Pharmaceuticals; Nivolumab/hyaluronidase-nvhy - Bristol-Myers Squibb/Ono Pharmaceuticals; ONO-4538HSC; Opdivo Qvantig

Latest Information Update: 05 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb; Ono Pharmaceutical
  • Class Antineoplastics; Antivirals; Glycoside hydrolases; Immunotherapies; Monoclonal antibodies; Polysaccharide lyases
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Hyaluronic acid modulators; Hyaluronidase replacements; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Adenocarcinoma; Colorectal cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Renal cell carcinoma; Squamous cell cancer; Urogenital cancer
  • Phase I Solid tumours

Most Recent Events

  • 29 May 2025 Registered for Adenocarcinoma (Combination therapy, Late-stage disease, Metastatic disease) in Liechtenstein, Norway, Iceland, European Union (SC)
  • 29 May 2025 Registered for Colorectal cancer (Metastatic disease, Second-line therapy or greater) in Iceland, Liechtenstein, Norway, European Union (SC)
  • 29 May 2025 Registered for Liver cancer (Second-line therapy or greater) in Iceland, Norway, Liechtenstein, European Union (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top